MRNS - Marinus Pharmaceuticals, Inc.
5.74 0.00 (0.00%)
After hours: 4:32PM EDT
| Previous Close | 5.72 |
| Open | 5.69 |
| Bid | 5.31 x 2200 |
| Ask | 6.09 x 1300 |
| Day's Range | 5.57 - 5.89 |
| 52 Week Range | 3.31 - 10.54 |
| Volume | 589,085 |
| Avg. Volume | 661,934 |
| Market Cap | 232.613M |
| Beta (3Y Monthly) | 2.88 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.74 |
| Earnings Date | Jul 30, 2018 - Aug 3, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 17.50 |
- GlobeNewswire•12 days ago
Marinus Pharmaceuticals Names Dr. Rolando Gutíerrez-Esteinou as VP of Clinical Development and Pharmacovigilance
Marinus Pharmaceuticals, Inc. (MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, announced the appointment of Rolando Gutíerrez-Esteinou, M.D., as Vice President of Clinical Development and Pharmacovigilance where he will primarily be responsible for the medical leadership of our postpartum depression (PPD) programs and drug safety. “Dr. Gutíerrez-Esteinou is a welcome addition to the management team at Marinus,” said Christopher Cashman, Chairman and CEO of Marinus Pharmaceuticals.
- GlobeNewswire•13 days ago
Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)
Marinus Pharmaceuticals, Inc. (MRNS) (the “Company”, “Marinus”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that the Compensation Committee of the Board of Directors of Marinus granted non-qualified stock options to purchase an aggregate of 120,000 shares of its common stock to a new employee, with a grant date of October 8, 2018. The options will vest and become exercisable as to 25 percent of the shares on the one-year anniversary of the recipient's start date, and will vest and become exercisable as to the remaining 75 percent of the shares in 36 equal monthly installments at the end of each month following the anniversary, subject to the employee's continued employment with Marinus on such vesting dates. The stock options were granted as inducements material to the new employee entering into employment with Marinus in accordance with NASDAQ Listing Rule 5635(c)(4), and are subject to the terms and conditions of a stock option agreement covering the grant.
- GlobeNewswire•17 days ago
Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Marinus Pharmaceuticals, Inc. (MRNS) (the “Company”, “Marinus”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that the Compensation Committee of the Board of Directors of Marinus granted non-qualified stock options to purchase an aggregate of 20,000 shares of its common stock each to two new employees, with grant dates of October 1 and October 3, 2018. The stock options were granted as inducements material to the new employees entering into employment with Marinus in accordance with NASDAQ Listing Rule 5635(c)(4), and are subject to the terms and conditions of a stock option agreement covering the grant. Marinus Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development of ganaxolone, which offers a new mechanism of action, demonstrated efficacy and safety, and convenient dosing to improve the lives of patients suffering from epilepsy and neuropsychiatric disorders.
- Simply Wall St.•24 days ago
What Kind Of Shareholders Own Marinus Pharmaceuticals Inc (NASDAQ:MRNS)?
A look at the shareholders of Marinus Pharmaceuticals Inc (NASDAQ:MRNS) can tell us which group is most powerful. Insiders often own a large chunk of younger, smaller, companies while huge Read More...
- GlobeNewswire•27 days ago
Marinus Completes Enrollment in its Magnolia Postpartum Depression Study
Marinus Pharmaceuticals, Inc. (MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, announced it has recently completed enrollment in its Magnolia Study – a Phase 2 clinical trial evaluating the safety, pharmacokinetics and efficacy of ganaxolone in women with postpartum depression. “The completion of enrollment in our Magnolia Study is an important milestone in studying PPD, for which there is currently no approved treatment,” said Christopher Cashman, chairman and CEO of Marinus Pharmaceuticals.
- ACCESSWIRE•28 days ago
Deals Pile Up as Big Biotech Looks to Capitalize on the Growing Market
HENDERSON, NV / ACCESSWIRE / September 20, 2018 / Small biotech companies have been receiving a ton of interest this year. Just last week, Boehringer Ingelheim's shopping spree continued with a €210m takeover of ViraTherapeutics, an oncolytic virus specialist it has been working with since 2016. Delcath Systems, Inc. (DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, has recently announced an amendment to its Registration trial in ocular melanoma liver metastases, a disease that has shown resistance to the new immunotherapies.
- GlobeNewswire•last month
Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Marinus Pharmaceuticals, Inc. (MRNS) (the “Company”, “Marinus”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that the Compensation Committee of the Board of Directors of Marinus granted non-qualified stock options to purchase an aggregate of 42,000 shares of its common stock to a new director and a new employee, with a grant date of September 19, 2018. Ganaxolone is a positive allosteric modulator of GABAA that acts on a well-characterized target in the brain known to have anti-seizure, anti-depressant and anti-anxiety effects.
- GlobeNewswire•2 months ago
Marinus Pharmaceuticals to Present at the Baird Healthcare Conference
Marinus Pharmaceuticals, Inc. (MRNS) (the “Company”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that Christopher M. Cashman, Chief Executive Officer will present a company overview at the Baird 2018 Healthcare Conference on Thursday, September 6, 2018 at 2:00 p.m. ET. The conference will take place in New York. Marinus Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development of ganaxolone, which offers a new mechanism of action, demonstrated efficacy and safety, and convenient dosing to improve the lives of patients suffering from epilepsy and neuropsychiatric disorders.
- GlobeNewswire•2 months ago
Analysis: Positioning to Benefit within MannKind, Chimerix, Superior Energy Services, Marinus Pharmaceuticals, Airgain, and Eagle Pharmaceuticals — Research Highlights Growth, Revenue, and Consolidated Results
NEW YORK, Aug. 28, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of MannKind ...
- Kiplinger•2 months ago
7 Biotech Stocks With Big Upcoming Catalysts
Are you ready? Biotech stocks provide a compelling opportunity for risk-tolerant investors looking for rich rewards. Regardless of market sentiment, economic data or trade wars, a key regulatory approval or trial data can send prices rocketing. Consider Madrigal Pharma (MDGL), which exploded by nearly 150% back in May following positive Phase 2 results for a liver-disease treatment. Of course, the opposite can also be true - prices can fall just as quickly if data or approvals fail to impress. That's why it's so crucial to conduct thorough research before investing in this high-potential (but high-risk) area of the market. For instance, using TipRanks, we can assess both the analyst consensus rating (all the stocks covered below are a "Moderate Buy" or "Strong Buy") and the expected upside potential based on recent ratings. Here are seven biotech stocks that could be catapulted higher by near-term catalysts. We'll also explore the pros' analysis and price targets for each company. SEE ALSO: The 18 Best Stocks to Buy for the Rest of 2018
- GlobeNewswire•2 months ago
Marinus Pharmaceuticals to Present at Wedbush/PacGrow Healthcare Conference
Marinus Pharmaceuticals, Inc. (MRNS) (the “Company”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that Edward F. Smith, Chief Financial Officer will present a company overview at the Wedbush/PacGrow Healthcare Conference on Tuesday, August 14, 2018 at 4:15 p.m. ET. The conference will take place in New York. Marinus Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development of ganaxolone, which offers a new mechanism of action, demonstrated efficacy and safety, and convenient dosing to improve the lives of patients suffering from epilepsy and neuropsychiatric disorders.
- Motley Fool•3 months ago
Here's Why Marinus Pharmaceuticals Inc. Fell as Much as 20.1% Today
The small biopharma announced second-quarter 2018 results and gave a business update.
- Associated Press•3 months ago
Marinus Pharmaceuticals: 2Q Earnings Snapshot
On a per-share basis, the Radnor, Pennsylvania-based company said it had a loss of 24 cents. Marinus Pharmaceuticals shares have declined 14 percent since the beginning of the year. The stock has nearly ...
- GlobeNewswire•3 months ago
Marinus Pharmaceuticals Provides Business Update and Second Quarter 2018 Financial Results
RADNOR, Pa., Aug. 02, 2018-- Marinus Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today provided ...
- GlobeNewswire•3 months ago
Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Marinus Pharmaceuticals, Inc. (MRNS) (the “Company”, “Marinus”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that the Compensation Committee of the Board of Directors of Marinus granted non-qualified stock options to purchase an aggregate of 50,000 shares of its common stock to a new employee, with a grant date of July 27, 2018. The stock options were granted as inducements material to the new employees entering into employment with Marinus in accordance with NASDAQ Listing Rule 5635(c)(4), and are subject to the terms and conditions of a stock option agreement covering the grant.
- Benzinga•3 months ago
Canaccord Previews Biotech Catalysts In The Second Half: Neurological Drugs In Focus
The biotech space represents a gold mine of opportunity for investors to multiply their investment returns, courtesy of the volatility generated by market-moving catalysts. In a note this week, Canaccord ...
- ACCESSWIRE•3 months ago
Free Technical Research on Marinus Pharma and Three More Biotech Equities
LONDON, UK / ACCESSWIRE / July 16, 2018 / If you want a free Stock Review on MRNS sign up now at www.wallstequities.com/registration. On Friday, July 13, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. Six out of nine sectors ended Friday's trading session in bullish territories.
- TheStreet.com•3 months ago
Pfizer Doesn't Look Fundamentally or Technically Strong
The best-looking trading group right now is the small oil stocks, but even those have thinned out after a few days of strong action. There are also a few biotech names making an effort to turn, but that's sparse, too. PFE also said that it's going to suspend drug-price increase that went into effect July 1 and will keep them on hold there until President Donald Trump unveils his plan to strengthen the U.S. health-care system.
- ACCESSWIRE•4 months ago
Free Technical Reports on MannKind and Three Additional Biotech Equities
This morning, WallStEquities.com is focused on the Biotech space, which is engaged in the research and development of new drugs, medical devices, and procedures. The industry includes the manufacturing and marketing of drugs as a result of direct research and development. Under evaluation today are these four equities: Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX), MannKind Corp. (NASDAQ: MNKD), Marinus Pharmaceuticals Inc. (NASDAQ: MRNS), and Neptune Technologies & Bioressources Inc. (NASDAQ: NEPT).
- Benzinga•5 months ago
Marinus Pharmaceuticals Has 3 Major Catalysts In 2018, Ladenburg Thalmann Says In Bullish Initiation
Marinus Pharmaceuticals Inc (NASDAQ: MRNS ) is a developer of ganaxolone, a therapy intended to treat patients with a rare genetic disorder, and initial data is "looking good," according to Ladenburg ...
